Refine
Year of publication
Document Type
- Article (77)
- Conference Proceeding (10)
- Preprint (5)
Language
- English (92) (remove)
Has Fulltext
- yes (92)
Is part of the Bibliography
- no (92)
Keywords
- ADHD (16)
- Depression (8)
- Bipolar disorder (7)
- Genetics (6)
- bipolar disorder (5)
- Human behaviour (4)
- Psychiatric disorders (4)
- Dopamine (3)
- Neuroscience (3)
- Physical activity (3)
- Suicide (3)
- Treatment (3)
- fMRI (3)
- Attention-deficit/hyperactivity disorder (2)
- Biomarker (2)
- Brain (2)
- Clinical genetics (2)
- Comorbidity (2)
- Diagnostic markers (2)
- Emotion regulation (2)
- Exercise (2)
- Inflammation (2)
- L-DOPA (2)
- Major depressive disorder (2)
- PARK2 (2)
- Predominant polarity (2)
- Primary care (2)
- attention (2)
- biomarker (2)
- continuous performance test (2)
- hyperactivity (2)
- impulsivity (2)
- machine learning (2)
- polygenic risk score (2)
- schizophrenia (2)
- 14-3-3 gene family (1)
- A2BP1 (1)
- ADHD differential diagnosis (1)
- AKI (1)
- Accidents (1)
- Adult-onset ADHD (1)
- Affect (1)
- Affective disorders (1)
- Agoraphobia (1)
- Ambulatory Assessment (1)
- Amino acids (1)
- Amisulpride (1)
- Amphetamine (1)
- Amygdala (1)
- Animal models (1)
- Antidepressant (1)
- Anxiolytic pharmacological therapy (1)
- Atomoxetine (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention deficit (1)
- Attention-deficit / hyperactivity disorder (1)
- Attentional bias (1)
- Batten disease (1)
- Behavioral tests (1)
- Big Five (1)
- Brain DNA methylation (1)
- Bright light therapy (1)
- Brms (1)
- Brodalumab (1)
- CAPON (1)
- CDH13 (1)
- CNVs (1)
- COMT (1)
- COVID-19 (1)
- Cardiac surgery (1)
- Circadian (1)
- Cln3 (1)
- Co-morbidity (1)
- Cognitive (1)
- Cognitive dysfunction (1)
- Cognitive enhancers of exposure therapy (1)
- Cognitive impairment (1)
- Comorbidities (1)
- Completed suicide (1)
- Copy number (1)
- Course (1)
- DTI (1)
- DYT1 (1)
- Developmental programming (1)
- Developmental trajectory (1)
- Diagnosis (1)
- Diagnostic medicine (1)
- Diagnostic test (1)
- Dietary intake (1)
- Differential diagnosis (1)
- Dot-probe task (1)
- EBM (1)
- Early (prenatal and postnatal) life experiences (1)
- Ecological Momentary Assessment (EMA) (1)
- Ecological momentary assessment (1)
- Energy (1)
- Environmental enrichment (1)
- Epigenetics (1)
- Euthymic phase (1)
- Evidence-based drug discovery (1)
- Explicit (1)
- Fruit fly (1)
- GHQ-28 (1)
- GWAS (1)
- Gaba (1)
- Gene (1)
- Genetic syndromes (1)
- Healthy Living Index (HLI) (1)
- Hippocampus (1)
- Hyperactivity (1)
- IL-17 (1)
- Imaging genetics (1)
- Immunity (1)
- Immunogenetics (1)
- Immunology (1)
- Implicit (1)
- Injuries (1)
- Intervention (1)
- KDIGO (1)
- LFP (1)
- Learning and memory (1)
- Lithium (1)
- Longitudinal (1)
- MDD (1)
- MVPA (1)
- Maintenance treatment (1)
- Mania (1)
- Maternal separation (1)
- Memory (1)
- Mental disorder (1)
- Mental health and psychiatry (1)
- Mental health disorders (1)
- Metabolic diseases (1)
- Methylphenidate (1)
- Mitochondrial dysfunction (1)
- Molecular neuroscience (1)
- Monetary incentive delay (1)
- Mood (1)
- Mouse (1)
- Multilevel two-part modelling (1)
- Multiplex immunoassay (1)
- NOS-I (1)
- NOS1AP (1)
- NPSR1 (1)
- Nesplora Aquarium (1)
- Neurodevelopmental disorder (1)
- Norepinephrine (1)
- Obesity (1)
- Outcome (1)
- Pandemic (1)
- Panic disorder (1)
- Patients (1)
- Personalized medicine (1)
- Phenylketonuria (PKU) (1)
- Physical fitness (1)
- Physical self-perception (1)
- Physicians (1)
- Polarity index (1)
- Polygenic risk score (1)
- Prediction (1)
- Predictive markers (1)
- Psychedelics (1)
- Psychiatric traits (1)
- Psychiatry (1)
- Qb-Test (1)
- QbTest® (1)
- Quality of life (1)
- R (1)
- RBFOX1 (1)
- RDoC (1)
- RNAi (1)
- Randomized controlled trial (1)
- Research article (1)
- Reward (1)
- Rodents (1)
- SARS-CoV2 (1)
- Schizophrenia (1)
- Scientific community (1)
- Seasonal variation (1)
- Self-efficacy (1)
- Self-esteem (1)
- Semicontinuous (1)
- Solar insolation (1)
- Stimulant (1)
- Stress resilience (1)
- Stress vulnerability/resilience genes (1)
- Striatum (1)
- Suicidal behavior (1)
- Suicidal thoughts (1)
- Suicide attempt (1)
- Sunlight (1)
- Synaptic dysfunction (1)
- TBSS (1)
- TOR1A (1)
- Trajectories (1)
- Two-hit hypothesis (1)
- Tyrosinemia (1)
- UPPS (1)
- Westphal-Paradigm (1)
- Working memory capacity (1)
- YWHAE (1)
- YWHAZ (1)
- Yoga (1)
- Zebrafish (1)
- accidents (1)
- adaptation (1)
- adeno-associated virus (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adversity (1)
- affective disorder (1)
- affective disorders (1)
- aggressiveness (1)
- aging (1)
- agreeableness (1)
- alcohol use disorder (1)
- allostasis (1)
- amisulpride (1)
- associative memory (1)
- attention deficit hyperactivity disorder (1)
- attention-deficit/hyperactivity disorder (1)
- autism (1)
- bipolar disorders (1)
- blood (1)
- body mass index (1)
- ceramides (1)
- children (1)
- cognition (1)
- common variant (1)
- common variants (1)
- coping (1)
- cross-sectional study (1)
- data science (1)
- dementia (1)
- depression (1)
- development (1)
- diabetes mellitus (1)
- disease modelling (1)
- dopamine (1)
- dynamic system (1)
- early recognition (1)
- endocannabinoids (1)
- epigenetics (1)
- euthymic (1)
- ex-Gaussian analysis (1)
- executive functions (1)
- expression studies (1)
- extraversion (1)
- face-name association task (1)
- fear conditioning (1)
- fear generalization (1)
- functional connectivity (1)
- gender (1)
- genetic phenotypes (1)
- genetic variants (1)
- gene×environment interactions (1)
- glucose metabolism (1)
- graph theory (1)
- hiPSC (1)
- homeostasis (1)
- inflammation (1)
- insula (1)
- insulin resistance (1)
- lifestyle (1)
- lipids (1)
- major depression (1)
- major depression (MD) (1)
- major depressive disorder (1)
- major depressive disorder (MDD) (1)
- maturation (1)
- mental health (1)
- metabolic syndrome (1)
- mitochondria (1)
- nNOS (1)
- naturalistic sample (1)
- neurodevelopment (1)
- neurodevelopmental disorders (1)
- neuropsychology (1)
- neuroticism (1)
- nitric oxide (1)
- obesity (1)
- pharmaco-fMRI (1)
- pharmacogenetics (1)
- prediabetes (1)
- proteome (1)
- psychiatric disorders (1)
- psychosocial stress (1)
- rare mendelian disorders (1)
- rare variant (1)
- rare variants (1)
- resting-state fMRI (1)
- resting‐state (1)
- risk genes (1)
- schizophrenia spectrum (1)
- skin conductance (1)
- stress (1)
- substance abuse disorder (1)
- tandem mass spectrometry (1)
- transcriptomics (1)
- ventral tegmental area (1)
- venturesomeness (1)
- viral gene transfer (1)
- white-matter (1)
- working memory (1)
Institute
- Medizin (92) (remove)
Attention-Deficit/Hyperactivity Disorder (ADHD) is frequently comorbid with other psychiatric disorders and also with somatic conditions, such as obesity. In addition to the clinical overlap, significant genetic correlations have been found between ADHD and obesity as well as body mass index (BMI). The biological mechanisms driving this association are largely unknown, but some candidate systems, like dopaminergic neurotransmission and circadian rhythm, have been suggested. Our aim was to identify the biological mechanisms underpinning the link between ADHD and obesity measures. Using the largest GWAS summary statistics currently available for ADHD (N=53,293), BMI (N=681,275), and obesity (N=98,697), we first tested the association of dopaminergic and circadian rhythm gene sets with each phenotype. This hypothesis-driven approach showed that the dopaminergic gene set was associated with both ADHD (P=5.81×10−3) and BMI (P=1.63×10−5), while the circadian rhythm gene set was associated with BMI only (P=1.28×10−3). We then took a data-driven approach by conducting genome-wide ADHD-BMI and ADHD-obesity gene-based meta-analyses, followed by pathway enrichment analyses. This approach further supported the implication of dopaminergic signaling in the link between ADHD and obesity measures, as the Dopamine-DARPP32 Feedback in cAMP Signaling pathway was significantly enriched in both the ADHD-BMI and ADHD-obesity gene-based meta-analysis results. Our findings suggest that dopaminergic neurotransmission, partially through DARPP-32-dependent signaling, is a key player underlying the genetic overlap between ADHD and obesity measures. Uncovering the shared etiological factors underlying the frequently observed ADHD-obesity comorbidity may have important implications in terms of preventive interventions and/or efficient treatment of these conditions.
Attention-Deficit/Hyperactivity Disorder (ADHD) and obesity are frequently comorbid, genetically correlated, and share brain substrates. The biological mechanisms driving this association are unclear, but candidate systems, like dopaminergic neurotransmission and circadian rhythm, have been suggested. Our aim was to identify the biological mechanisms underpinning the genetic link between ADHD and obesity measures and investigate associations of overlapping genes with brain volumes. We tested the association of dopaminergic and circadian rhythm gene sets with ADHD, body mass index (BMI), and obesity (using GWAS data of N=53,293, N=681,275, and N=98,697, respectively). We then conducted genome-wide ADHD-BMI and ADHD-obesity gene-based meta-analyses, followed by pathway enrichment analyses. Finally, we tested the association of ADHD-BMI overlapping genes with brain volumes (primary GWAS data N=10,720–10,928; replication data N=9,428). The dopaminergic gene set was associated with both ADHD (P=5.81×10−3) and BMI (P=1.63×10−5), the circadian rhythm was associated with BMI (P=1.28×10−3). The genome-wide approach also implicated the dopaminergic system, as the Dopamine-DARPP32 Feedback in cAMP Signaling pathway was enriched in both ADHD-BMI and ADHD-obesity results. The ADHD-BMI overlapping genes were associated with putamen volume (P=7.7×10−3; replication data P=3.9×10−2) – a brain region with volumetric reductions in ADHD and BMI and linked to inhibitory control. Our findings suggest that dopaminergic neurotransmission, partially through DARPP-32-dependent signaling and involving the putamen, is a key player underlying the genetic overlap between ADHD and obesity measures. Uncovering shared etiological factors underlying the frequently observed ADHD-obesity comorbidity may have important implications in terms of prevention and/or efficient treatment of these conditions.
Attention-Deficit/Hyperactivity Disorder (ADHD) and obesity are frequently comorbid, genetically correlated, and share brain substrates. The biological mechanisms driving this association are unclear, but candidate systems, like dopaminergic neurotransmission and circadian rhythm, have been suggested. Our aim was to identify the biological mechanisms underpinning the genetic link between ADHD and obesity measures and investigate associations of overlapping genes with brain volumes. We tested the association of dopaminergic and circadian rhythm gene sets with ADHD, body mass index (BMI), and obesity (using GWAS data of N = 53,293, N = 681,275, and N = 98,697, respectively). We then conducted genome-wide ADHD–BMI and ADHD–obesity gene-based meta-analyses, followed by pathway enrichment analyses. Finally, we tested the association of ADHD–BMI overlapping genes with brain volumes (primary GWAS data N = 10,720–10,928; replication data N = 9428). The dopaminergic gene set was associated with both ADHD (P = 5.81 × 10−3) and BMI (P = 1.63 × 10−5); the circadian rhythm was associated with BMI (P = 1.28 × 10−3). The genome-wide approach also implicated the dopaminergic system, as the Dopamine-DARPP32 Feedback in cAMP Signaling pathway was enriched in both ADHD–BMI and ADHD–obesity results. The ADHD–BMI overlapping genes were associated with putamen volume (P = 7.7 × 10−3; replication data P = 3.9 × 10−2)—a brain region with volumetric reductions in ADHD and BMI and linked to inhibitory control. Our findings suggest that dopaminergic neurotransmission, partially through DARPP-32-dependent signaling and involving the putamen, is a key player underlying the genetic overlap between ADHD and obesity measures. Uncovering shared etiological factors underlying the frequently observed ADHD–obesity comorbidity may have important implications in terms of prevention and/or efficient treatment of these conditions.
Background: The COVID-19 pandemic led to a higher incidence of depression and a worsening of psychiatric conditions, while pre-existing constraints of the healthcare system and safety regulations limited psychiatric care.
Aims: We investigated the impact of the pandemic on the clinical care of patients with a single episode (SE-MDD) or major depressive disorder (MDD) in Germany.
Methods: Nationwide inpatient data were extracted from the German Institute for Hospital Remuneration System for 2020 and 2021 (depression data) and the Robert Koch Institute (COVID-19 incidence). Changes in inpatients were tested with linear regression models. Local cases of depression in our department compared to 2019 were explored with one-way ANOVA and Dunnett's test.
Results: Across Germany, the inpatient numbers with both SE-MDD and MDD declined by more than 50% during three out of four COVID-19 waves. Higher COVID-19 incidence correlated with decreased inpatient numbers. In our department, fewer MDD inpatients were treated in 2020 (adj. p < 0.001) and 2021 (adj. p < 0.001) compared to 2019, while the number of SE-MDD inpatients remained stable. During this period fewer elective and more emergency inpatients were admitted. In parallel, MDD outpatient admissions increased in 2021 compared to 2019 (adj. p = 0.002) and 2020 (adj. p = 0.003).
Conclusion: During high COVID-19 infection rates, MDD patients received less inpatient care, which might cause poor outcomes in the near future. These data highlight the necessity for improved infrastructure in the in- and outpatient domains to facilitate accessibility to adequate care.
Background: Nitric oxide synthase 1 adaptor protein (NOS1AP; previously named CAPON) is linked to the glutamatergic postsynaptic density through interaction with neuronal nitric oxide synthase (nNOS). NOS1AP and its interaction with nNOS have been associated with several mental disorders. Despite the high levels of NOS1AP expression in the hippocampus and the relevance of this brain region in glutamatergic signalling as well as mental disorders, a potential role of hippocampal NOS1AP in the pathophysiology of these disorders has not been investigated yet.
Methods: To uncover the function of NOS1AP in hippocampus, we made use of recombinant adeno-associated viruses to overexpress murine full-length NOS1AP or the NOS1AP carboxyterminus in the hippocampus of mice. We investigated these mice for changes in gene expression, neuronal morphology, and relevant behavioural phenotypes.
Findings: We found that hippocampal overexpression of NOS1AP markedly increased the interaction of nNOS with PSD-95, reduced dendritic spine density, and changed dendritic spine morphology at CA1 synapses. At the behavioural level, we observed an impairment in social memory and decreased spatial working memory capacity.
Interpretation: Our data provide a mechanistic explanation for a highly selective and specific contribution of hippocampal NOS1AP and its interaction with the glutamatergic postsynaptic density to cross-disorder pathophysiology. Our findings allude to therapeutic relevance due to the druggability of this molecule.
Studying the visual system with fMRI often requires using localizer paradigms to define regions of interest (ROIs). However, the considerable interindividual variability of the cerebral cortex represents a crucial confound for group-level analyses. Cortex-based alignment (CBA) techniques reliably reduce interindividual macroanatomical variability. Yet, their utility has not been assessed for visual field localizer paradigms, which map specific parts of the visual field within retinotopically organized visual areas. We evaluated CBA for an attention-enhanced visual field localizer, mapping homologous parts of each visual quadrant in 50 participants. We compared CBA with volume-based alignment and a surface-based analysis, which did not include macroanatomical alignment. CBA led to the strongest increase in the probability of activation overlap (up to 86%). At the group level, CBA led to the most consistent increase in ROI size while preserving vertical ROI symmetry. Overall, our results indicate that in addition to the increased signal-to-noise ratio of a surface-based analysis, macroanatomical alignment considerably improves statistical power. These findings confirm and extend the utility of CBA for the study of the visual system in the context of group analyses. CBA should be particularly relevant when studying neuropsychiatric disorders with abnormally increased interindividual macroanatomical variability.
Why do humans cooperate and often punish norm violations of others? In the present study, we sought to investigate the genetic bases of altruistic punishment (AP), which refers to the costly punishment of norm violations with potential benefit for other individuals. Recent evidence suggests that norm violations and unfairness are indexed by the feedback-related negativity (FRN), an anterior cingulate cortex (ACC) generated neural response to expectancy violations. Given evidence on the role of serotonin and dopamine in AP as well as in FRN-generation, we explored the impact of genetic variation of serotonin and dopamine function on FRN and AP behavior in response to unfair vs. fair monetary offers in a Dictator Game (DG) with punishment option. In a sample of 45 healthy participants we observed larger FRN amplitudes to unfair DG assignments both for 7-repeat allele carriers of the dopamine D4 receptor (DRD4) exon III polymorphism and for l/l-genotype carriers of the serotonin transporter gene-linked polymorphic region (5-HTTLRP). Moreover, 5-HTTLPR l/l-genotype carriers punished unfair offers more strongly. These findings support the role of serotonin and dopamine in AP, potentially via their influence on neural mechanisms implicated in the monitoring of expectancy violations and their relation to impulsive and punishment behavior.
Highlights
• A panel of 20 biomarkers was identified capable of differentiating BD patients from controls.
• Excellent discrimination between established BD patients and controls.
• Good to excellent discrimination between misdiagnosed BD patients and first onset MDD patients.
• Fair to good discrimination between pre-diagnostic BD patients and controls.
• Study demonstrates the potential utility of a protein biomarker panel as a diagnostic test for BD.
Abstract
Background: Bipolar disorder (BD) is a costly, devastating and life shortening mental disorder that is often misdiagnosed, especially on initial presentation. Misdiagnosis frequently results in ineffective treatment. We investigated the utility of a biomarker panel as a diagnostic test for BD.
Methods and findings: We performed a meta-analysis of eight case-control studies to define a diagnostic biomarker panel for BD. After validating the panel on established BD patients, we applied it to undiagnosed BD patients. We analysed 249 BD, 122 pre-diagnostic BD, 75 pre-diagnostic schizophrenia and 90 first onset major depression disorder (MDD) patients and 371 controls. The biomarker panel was identified using ten-fold cross-validation with lasso regression applied to the 87 analytes available across the meta-analysis studies.
We identified 20 protein analytes with excellent predictive performance [area under the curve (AUC) ⩾ 0.90]. Importantly, the panel had a good predictive performance (AUC 0.84) to differentiate 12 misdiagnosed BD patients from 90 first onset MDD patients, and a fair to good predictive performance (AUC 0.79) to differentiate between 110 pre-diagnostic BD patients and 184 controls. We also demonstrated the disease specificity of the panel.
Conclusions: An early and accurate diagnosis has the potential to delay or even prevent the onset of BD. This study demonstrates the potential utility of a biomarker panel as a diagnostic test for BD.